In addition to the products presently in human clinical trials, we have a number of products that may be ready for late stage clinical study initiation in the future. These include iganidipine to enhance ocular nerve blood flow; new formulation of latanoprost, a prostaglandin, for the treatment of glaucoma; ecabet sodium for the treatment of dry eyes, and bromfenac as an adjunct therapy for the treatment of age-related macular degeneration (AMD).